BRD4 and malignant peripheral nerve sheath tumor: To further investigate whether BRD4 can serve as a target for treatment we determined the sensitivity of our cell line panel consisting of a neurofibroma and 5 MPNST cell lines, to the BET bromodomain inhibitor JQ1 (Fig 2A).